瑞巴派特联合四联疗法治疗幽门螺杆菌阳性慢性胃炎的临床观察

Clinical Study on treatment of helicobacter pylori positive chronic gastritis with rebamipide combined with quadruple therapy

目的观察瑞巴派特联合四联疗法治疗幽门螺杆菌(Hp)阳性慢性胃炎患者的临床疗效。方法将Hp阳性慢性胃炎患者140例随机分为2组,每组70例。对照组给予奥美拉唑20 mg+阿莫西林1 000 mg+克拉霉素500 mg+枸橼酸铋钾颗粒220 mg治疗。治疗组在对照组治疗的基础上给予瑞巴派特1.0 g治疗。比较2组治疗2周后Hp根除率、临床疗效和不良反应。结果治疗后治疗组Hp根除率为92.86%高于对照组的84.29%,差异有统计学意义(P<0.05)。治疗前2组消化道症状评分比较差异无统计学意义(P>0.05);治疗后2组消化道症状评分均降低(P<0.05),且治疗组低于对照组(P<0.05)。治疗组不良反应发生率为7.14%,对照组不良反应发生率为8.57%,2组比较差异无统计学意义(P>0.05)。结论瑞巴派特联合四联疗法治疗Hp阳性慢性胃炎临床疗效显著,且安全性高,值得临床推广。

Objective To investigate the clinical efficacy of rebamipide combined with quadruple therapy in the treatment of Helicobacter pylori positive chronic gastritis. Methods 140 patients with helicobacter pylori positive chronic gastritis were randomly divided into control group（70 cases） and treatment group（70 cases）. The control group was given omeprazole 20 mg ＋ amoxicillin 1 000 mg ＋ clarithromycin 500 mg ＋ potassium bismuth citrate particles 220 mg. On the basis of control group,the treatment group was given rebamipide 1. 0 g treatment. After 2 weeks of treatment,the eradication rate,clinical efficacy and adverse reactions of Helicobacter pylori in two groups were compared. Results After treatment,the eradication rate of Hp in the treatment group was 92. 86% higher than 84. 29% in the control group,the difference was statistically significant（P〈0. 05）. There was no significant difference in digestive symptom scores between the two groups before treatment（P〈0. 05）;After treatment,the scores of gastrointestinal symptoms in both groups decreased（P〈0. 05）,and were lower in the treatment group was lower than that in the control group（P〈0. 05）. The incidence of adverse reactions in the treatment group was7. 14%,and the incidence of adverse reactions in the control group was 8. 57%,there was no significant difference between the two groups（P〈0. 05）. Conclusion Rebamipide combination of quadruple therapy in the treatment of Helicobacter pylori positive chronic gastritis in patients with good clinical efficacy,high safety,worthy of clinical promotion.